Pivotal topline data from the phase 1/2 TRIDENT-1 trial of repotrectinib in patients with ROS1+ advanced non-small cell lung cancer (NSCLC)

B. C. Cho, J. Lin, D. R. Camidge, V. Velcheti, B. Solomon, S. Lu, K. H. Lee, S. W. Kim, S. Kao, R. Diadziuskzko, M. Beg, M. Nagasaka, E. Felip, B. Besse, C. Springfeld, S. Popat, J. Wolf, D. Trone, S. Stopatschinskaja, A. Drilon

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)S1-S2
JournalEuropean Journal of Cancer
Publication statusPublished - 2022 Oct

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this